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Mitogenic activation of expression of immediate-early
genes, such as c-fos, is controlled through signal-induced
phosphorylation of constitutively bound transcription
factors that is correlated with a nucleosomal response
that involves inducible chromatin modifications, such as
histone phosphorylation and acetylation. Here we have
explored a potential role for the transcription factor
NF-B and its associated signaling components in medi-
ating induction of c-fos gene expression downstream of
epidermal growth factor (EGF)-dependent signaling.
Here we show that EGF treatment of quiescent fibroblast
does not induce the classical pathway of NF-B activation
through IB kinase (IKK)-directed IB phosphorylation.
Interestingly, efficient induction of c-fos transcription re-
quires IKK, one of the subunits of the IB kinase com-
plex. The NF-B subunit, p65/RelA, is found constitutively
associated with the c-fos promoter, and knock-out of this
transcription factor significantly reduces c-fos gene ex-
pression. Importantly, EGF induces the recruitment of
IKK to the c-fos promoter to regulate promoter-specific
histone H3 Ser10 phosphorylation in a manner that is
independent of p65/RelA. Collectively, our data demon-
strate that IKK and p65/RelA contribute significantly to
EGF-induced c-fos gene expression in a manner independ-
ent of the classical, IB degradation, p65/RelA nuclear
accumulation response pathway.
NF-B is a widely studied dimeric transcription factor that is
inducible by inflammatory cytokines, lipopolysaccharide, and
other regulatory stimuli (1–5). The five members of the mam-
malian NF-B family are RelA/p65, c-Rel, p50/NF-B1, p52/
NF-B2, and RelB. Control of NF-B activation is generally
considered to be at the level of release from the IB inhibitory
proteins, which maintain NF-B largely in the cytoplasmic
compartment. Following exposure of cells to inflammatory cy-
tokines, the IB kinase (IKK)1 complex is activated and phos-
phorylates IB proteins on N-terminal serines leading to their
ubiquitination and subsequent proteasome-dependent degra-
dation. This process frees NF-B to accumulate in the nucleus
and to associate with specific gene regulatory regions to control
gene expression (1–5). The IKK complex contains two highly
conserved catalytic subunits, namely IKK and IKK, of which
IKK appears to be the dominant kinase controlling IB phos-
phorylation downstream of cytokine-induced signaling (1, 3).
However little to no information exists regarding direct roles
for IKK or NF-B in controlling growth factor-induced gene
expression.
EGF family members interact with receptors belonging to
the EGF receptor family, including EGF receptor, epidermal
growth factor receptor family protein (ErbB)2, ErbB3, and
ErbB4 (6). Interaction of these signaling molecules with the
receptors initiates intracellular signaling cascades that lead to
activation of a number of transcription factors such as AP-1
and STATs (7). It has previously been reported that EGF in-
duces NF-B nuclear levels in cell types such as A431 cells and
in several breast cancer cell lines that overexpress EGF recep-
tor (8). However, it remains inconclusive whether EGF signal-
ing to NF-B occurs in EGF receptor-normalized cell lines such
as fibroblasts, and relevant gene targets are unknown.
The immediate early genes (including c-fos, c-jun, and c-myc)
are characterized by their rapid inducibility in response to a
variety of signals, including mitogenic stimulation (9). c-fos has
been the most extensively studied of this group of genes rela-
tive to induction of gene expression, with evidence demonstrat-
ing the involvement of sequence-specific transcription factors
and associated co-factors controlling transcription induction in
a manner dependent on the activation of upstream signal
transduction cascades (10–12). A key regulatory element in the
c-fos promoter is the serum response element (SRE), which
interacts in a constitutive manner with the serum response
ternary complex containing SRF, Elk-1, and the transcriptional
co-activator CBP/p300 (10, 11, 13, 14). It has been demon-
strated that phosphorylation of Elk-1 by MAPKs leads to the
activation of the ternary complex-associated CBP/p300 histone
acetyltransferase co-activator (14). Additionally, the c-fos pro-
moter undergoes inducible histone H3 phosphorylation and
acetylation following mitogenic stimulation that correlates
with immediate-early gene induction (15–17). The kinase that
controls histone H3 phosphorylation downstream of mitogen-
induced signaling has been proposed to be either MSK1/2 or
ribosomal S6 Kinase 2 (18, 19). More recent evidence supports
the role of MSK1/2 in controlling this response (18). Recently
we and others (20, 21) described IKK as a critical kinase
* This work was supported by National Institutes of Health Grants
RO1 AI35098 and RO1 CA73756 (to A. S. B.) and by a grant from the
Waxman Cancer Research Foundation. The costs of publication of this
article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
 To whom correspondence should be addressed: 22-000 Lineberger
Comprehensive Cancer Center, CB#7295, University of North Carolina,
Chapel Hill, NC 27599. Tel.: 919-966-3652; Fax: 919-966-0444;
E-mail: jhall@med.unc.edu.
1 The abbreviations used are: IKK, IB kinase; EGF, epidermal
growth factor; STAT, signal transducers and activators of transcrip-
tion; SRE, serum response element; CBP, cAMP-responsive element-
binding protein-binding protein; MAPK, mitogen-activated protein
kinase; TNF, tumor necrosis factor; MEF, mouse embryonic fibro-
blast; ChIP, chromatin immunoprecipitation; Tricine, N-[2-hydroxy-
1,1-bis(hydroxymethyl)ethyl]glycine; SRF, serum response factor;
MSK, mitogen- and stress-activated protein kinase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 30, Issue of July 23, pp. 31183–31189, 2004
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 31183
This is an Open Access article under the CC BY license.
involved in controlling TNF-induced H3 Ser10 phosphorylation
at certain NF-B-dependent promoters in a manner dependent
on the recruitment of RelA/p65 to the promoters. Here we have
analyzed the potential involvement of the p65/RelA subunit of
NF-B and IKK in controlling EGF-induced c-fos gene
expression.
EXPERIMENTAL PROCEDURES
Cells and Reagents—IKK wild-type, IKK/, and IKK/ MEFs
were provided by I. Verma and M. Karin. IKK reconstituted MEFs
(IKK/) were provided by E. Dejardin and D. Green. Antibodies
against IB, CBP, tubulin, and mouse IgG were obtained from Santa
Cruz. The p65/RelA-specific antibody was obtained from Rockland, Inc.
Antibodies specific for IKK, phospho-Ser10-H3 and acetyl-H3 at Lys9
or Lys14 were obtained from Upstate Biotechnology Inc. Phospho-
MEK1/2 and phospho-Elk-1 antibodies were obtained from Cell Signal-
ing. EGF (Upstate Biotechnology Inc.) was used at a final concentration
of 50 ng/ml.
Chromatin Immunoprecipitation Assay—ChIP analysis was per-
formed following a protocol provided by Upstate Biotechnology, Inc.
under modified conditions and as previously described (20). The follow-
ing promoter-specific primers were used; primer pair CACGGCCGGTC-
CCTGTTGTTC and GTCGCGGTTGGAGTAGTAGGCG was used to
amplify the proximal region of the c-fos promoter. The primers for
-globin are CAGCATGTGCTGAGGACTTGG and ACTGCCTTCA-
GAGAATCGCCC. Quantitative real time PCR was performed in trip-
licate to determine the association of phospho-Ser10-H3, acetyl-Lys9-
H3, and acetyl-Lys14 with the c-fos promoter by using the above
oligonucleotide primers and input DNA standards diluted in 3-fold
increment from 10 to 0.01% with SYBR Green Master Mix and the ABI
Prism 7700 sequence detection system.
Quantitative Real Time PCR—Total RNA was prepared from MEF,
IKK/, IKK/, IKK/, or p65/ cells using TRIzol (Invitrogen)
as recommended by the manufacturer. For real time PCR, the cDNA
was prepared with random primers (Invitrogen) and analyzed in trip-
licate with the SYBR Green Master Mix (Qiagen) for 15 min at 95 °C for
initial denaturing, followed by 40 cycles of 95 °C for 30 s and 63 °C for
30 s in the ABI sequence detection system. The oligonucleotide primers
used to analyzed IB transcripts contained the sequences 5-GATC-
CGCCAGGTGAAGGG-3 and 5-GCAATTTCTGGCTGGTTGG-3.
Primers used to analyze the c-fos and 18 S ribosomal RNAs were
obtained using an Ambion gene-specific relative reverse transcription-
PCR kit with the suggested conditions.
Western Blot Analysis—Western blot analysis was performed after
preparing nuclear, cytoplasmic, or whole cell extracts and separating
proteins by SDS-PAGE followed by immunoblotting with antibodies as
indicated. Extractions of acid-soluble proteins were done according to
the protocol described by Upstate Biotechnology, Inc. and resolved on
10–20% Tris-Tricine SDS-PAGE gels.
RESULTS
Analysis of the Classical NF-B Activation Pathway in Re-
sponse to EGF Stimulation of MEFs—It has previously been
reported that EGF induces NF-B nuclear levels in cell types
that overexpress EGF receptor, such as A431 cells and certain
breast cancer cell lines (8). We sought to determine whether EGF
signaling activates the classical NF-B pathway in cells that do
not express high levels of the EGF receptor. Thus, EGF-treated
mouse embryonic fibroblasts were analyzed for the characteristic
degradation of IB and nuclear accumulation of the p65 NF-B
subunit typically associated with the TNF response. MEFs were
stimulated with EGF and assayed for degradation of IB
through Western blot analysis. Interestingly, EGF did not result
in any significant level of IB degradation (Fig. 1A). Addition-
ally, analysis of nuclear and cytoplasmic extracts from EGF-
treated MEFs did not reveal detectable nuclear translocation of
p65 (Fig. 1B), although similar analysis using TNF results in
strong IB degradation and p65 nuclear accumulation (Ref. 20
and data not shown). This is consistent with previous reports
indicating that maximal nuclear accumulation of p65 is largely
dependent on IKK-directed IB phosphorylation. We previously
reported that the subcellular localization of IKK in unstimu-
lated MEFs is both nuclear and cytoplasmic and that IKK
undergoes a nuclear translocation event in response to TNF
stimulation (20). To determine whether EGF induces a sim-
ilar response, IKK levels were examined in nuclear and
cytoplasmic extracts by Western analysis. Similar to p65,
nuclear levels of IKK remained unchanged in response to
EGF (Fig. 1B). NF-B DNA binding potential, analyzed by
electrophoretic mobility shift assay, did not show any appre-
ciable increase in response to EGF (data not shown). Addi-
tionally, real time PCR analysis of wild-type MEFs demon-
strated only a modest induction of expression of the NF-B-
dependent IB gene in response to EGF in contrast to the
stronger inducible profile observed for induction of c-fos gene
expression (Fig. 1C). In contrast, TNF strongly activated the
IB gene and only weakly induced c-fos gene expression
(Fig. 1D), as previously reported (22). Taken together, these
results demonstrate that EGF does not activate the classical
NF-B activation pathway in mouse embryonic fibroblasts.
FIG. 1. EGF does not activate the classical NF-B activation
pathway in MEFs. A, detection of IB protein levels in EGF-stimu-
lated IKK wild-type MEFs. The cells were serum-starved for 48 h and
treated with EGF (50 ng/ml) at the indicated time points. Western
analysis was performed with anti-IB (top panel) and anti-tubulin
(bottom panel) as a loading control. B, analysis of the subcellular local-
ization of p65 NF-B subunit and IKK in EGF-treated MEFs. MEFs
were stimulated with EGF as in A, fractionated into cytoplasmic (CE)
and nuclear (NE) fractions, and then analyzed directly by Western
blotting with IKK and p65 antibodies. C, real time PCR analysis was
performed to measure the endogenous levels of IB or c-fos mRNA in
EGF (50 ng/ml) stimulated IKK wild-type MEFs. Quiescent cells were
treated with EGF at the indicated time points. The values are reported
as molecules of gene of interest (GOI), IB or c-fos, per attomol of 18 S
rRNA copies. D, real time PCR analysis of endogenous levels of IkB or
c-fos mRNA in TNF-treated (10 ng/ml) quiescent IKK wild-type MEFs.
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IKK Is Required for Optimal EGF-induced c-fos Gene
Expression—Previously, we had found that IKK contributes
to cytokine-induced gene expression. Thus, we addressed
whether the loss of IKK has an observable affect on c-fos gene
expression in response to EGF. Analysis of c-fos gene expres-
sion was measured by reverse transcription-PCR (Fig. 2A) and
independently by quantitative real time PCR analysis (Fig. 2B)
in wild-type MEFs and MEFs deficient for either IKK or
IKK. MEFs were maintained in low serum (0.5% fetal bovine
serum) for 48 h followed by EGF stimulation for the indicated
times to induce c-fos gene expression. As expected, wild-type
MEFs exhibited rapid induction of c-fos mRNA with peak levels
occurring 15 min after EGF stimulation, which decreased by
the 1-h time point (Fig. 2). Interestingly, induction of c-fos in
IKK/ MEFs was considerably reduced and more transient
following EGF stimulation (Fig. 2). Although induction of c-fos
was reduced at the 15-min time point in IKK/ cells, the
levels were more comparable with wild-type cells following 30
min of EGF stimulation (Fig. 2). Restoration of IKK-deficient
cells with wild-type IKK (IKK/) resulted in strong c-fos
expression following EGF treatment (Fig. 2B). The enhanced
level of c-fos gene expression in the IKK/ MEFs is likely due
to the relatively high expression of reconstituted IKK in these
cells (data not shown). Additionally, a similar requirement for
IKK in the inducible regulation of two other immediate-early
genes, c-myc and Fra-2, was observed (data not shown). These
data provide evidence that IKK is required for optimal EGF-
induced c-fos gene expression.
The Loss of IKK Does Not Affect EGF-induced Signaling
Pathways—One possible mechanism for the reduction of c-fos
gene expression observed in the IKK/ MEFs may involve
inhibition of EGF-induced signaling pathways. Therefore, we
investigated the effect of EGF on MAPK activation in IKK-
deficient cells by Western blot analysis using phospho-specific
antibodies. Treatment of wild-type MEFs with EGF resulted in
the induction of MEK1/2 phosphorylation within 10 min and
decreased after 30 min (Fig. 3A). Induction of MEK1/2 phos-
phorylation in IKK/ MEFs was similar to wild-type MEFs
with slight kinetic differences in activation (Fig. 3A). MAPK-
directed phosphorylation of Elk-1 was analyzed by immuno-
blotting with a phospho-specific Elk-1 antibody. Inducible and
transient levels of Elk-1 phosphorylation were detected in both
wild-type and IKK-deficient MEFs (Fig. 3B). These results
indicate no significant defect in MAPK activation in IKK/
cells and suggest that the altered induction in c-fos gene ex-
pression in IKK/ cells is downstream of MAPK activation,
specifically at the level of c-fos gene regulation.
Recruitment of IKK to the Endogenous c-fos Promoter Is
Enhanced in Response to EGF—Prior studies have correlated
enhanced H3 Ser10 phosphorylation with transcriptional induc-
tion of immediate-early genes, such as c-fos and c-myc, upon
mitogenic treatment (15–17, 19). However, the promoter asso-
ciation of potential H3 Ser10 kinases has not been explored.
Thus, we investigated whether IKK is recruited to the c-fos
promoter in response to EGF in a manner associated with
specific histone modifications. Specifically, MEFs were main-
tained for 48 h in 0.5% serum. Quiescent cells were treated
with EGF (50 ng/ml) for various times, DNA and protein was
cross-linked with formaldehyde, and DNA was sonicated to
shear chromatin into average fragments of 1 kb. Subse-
quently, protein-DNA complexes were immunoprecipitated us-
ing antibodies that specifically recognize phospho-Ser10 histone
H3, acetyl-Lys9-H3, or acetyl-Lys14-H3 in parallel with an
IKK-specific antibody. DNA recovered from the antibody-
bound fractions as well as the DNA from input chromatin
(input) were analyzed by semi-quantitative PCR using primers
specific for the proximal region of the c-fos promoter. The
specificity for all ChIP assays was demonstrated both by the
absence of c-fos amplification in the mock samples immunopre-
cipitated with or without an irrelevant antibody, IgG, and by
analysis of the transcriptionally inactive -globin locus (data
not shown).
In wild-type MEFs, stimulation with EGF led to an increase
of H3 Ser10 phosphorylation at the c-fos promoter, with peak
levels occurring at the 10-min time point that declined to un-
stimulated levels 1 h following EGF stimulation (Fig. 4A, left
panel). In contrast to H3 Ser10 phosphorylation, acetylation of
H3 at Lys9 and Lys14 was detected in unstimulated cells with
a modest increase detected following EGF stimulation. Inter-
estingly, association of IKK with the c-fos promoter was de-
tectable at low levels in unstimulated cells and increased tran-
siently in response to EGF, with enhanced association
occurring after 10 min of EGF treatment (Fig. 4A, left panel).
This analysis demonstrates that IKK association with the
c-fos promoter correlates with induced H3 Ser10 phosphoryla-
tion levels in quiescent MEFs stimulated with EGF.
FIG. 2. IKK is required for optimal
EGF-induced expression of c-fos. A,
reverse transcription-PCR analysis was
performed to measure endogenous mRNA
levels of c-fos after EGF stimulation.
Quiescent IKK wild-type (left panel),
IKK / (middle panel), or IKK/
MEFs were treated with EGF (50 ng/ml)
at the indicated time points and then har-
vested. Levels of 18 S rRNA were also
measured as a control. B, real time PCR
analysis was performed to quantitate the
endogenous levels of c-fos mRNA. Quies-
cent IKK wild-type, IKK/, IKK/, or
IKK/ reconstituted MEFs were
treated with EGF at the indicated time
points, similar to A. The values are re-
ported as molecules of c-fos per attomol of
18 S rRNA copies.
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IKK Is Required for EGF-induced H3 Ser10 Phosphorylation
at the c-fos Promoter—To determine whether IKK is required
for EGF-stimulated H3 Ser10 phosphorylation at the c-fos pro-
moter, ChIP assays were performed using quiescent IKK/
MEFs. In contrast to wild-type MEFs (Fig. 4A, left panel),
enrichment for H3 Ser10 phosphorylation at the c-fos promoter
was undetected in IKK/ MEFs following EGF treatment
(Fig. 4A, middle panel). Additionally, the kinetic profiles of
Lys9- and Lys14-acetylated H3 were similar to wild-type cells;
however, reduced levels of acetylated H3 at Lys19 or Lys14 were
detected in IKK/ cells. Next, quantification of ChIP DNA by
real time PCR was performed to measure the amount of c-fos
genomic DNA that co-immunoprecipitated with the specific
histone modifications in wild-type and IKK/ cells relative to
total input chromatin. These results show that in IKK/
MEFs, H3 Ser10 phosphorylation levels are quantitatively re-
duced most significantly after 10 min of EGF treatment with
more comparable levels to wild type at later time points (Fig.
4B). Both Lys9- and Lys14-acetylated H3 show modest induc-
tion in response to EGF in wild-type MEFs. However, induction
and overall levels of acetylated H3 are reduced in IKK/
MEFs (Figs. 4, C and D).
Next, to more directly address a potential requirement for
IKK in modulating H3 Ser10 phosphorylation at the c-fos
promoter, ChIP assays were performed using IKK-null MEFs
where wild-type IKK was restored via stable expression
(indicated as IKK/). ChIP assays revealed that H3 Ser10
phosphorylation levels were restored in response to EGF in
IKK/ MEFs with slight differences in kinetics as com-
pared with wild-type cells, with peak levels occurring after 15
min of EGF treatment (Fig. 4A, right panel). The kinetic
profile of IKK recruitment was delayed as compared with
wild type with peak levels of promoter-associated IKK de-
tected after 15 min of EGF treatment. Additionally, the ki-
netic profiles for Lys9- and Lys14-acetylated H3 were compa-
rable with wild-type MEFs. Overall, the recruitment of IKK
at the c-fos promoter coincided with and was required for
promoter-associated H3 Ser10 phosphorylation following EGF
treatment.
IKK Controls Global Levels of EGF-induced Phosphoryla-
tion of Histone H3 on Ser10—To address whether IKK plays a
broader role in regulating global levels of histone H3 phospho-
rylation, core histones were acid-extracted from EGF-treated
wild-type MEFs or IKK-deficient cells (IKK/) and exam-
ined by Western blot analysis using an antibody specific to
phospho-histone H3 (Ser10). As expected, wild-type MEFs ex-
hibit inducible H3 Ser10 phosphorylation in response to EGF in
a time-dependent manner (Fig. 4E). This histone modification
was visible within 15 min after the addition of EGF with
overall levels decreasing between 30 and 60 min post-
induction. Although H3 Ser10 phosphorylation levels in
IKK/ MEFs were similar to wild type after 15 min of EGF
treatment, overall levels were lost at the later time points
(Fig. 4E). IKK/ MEFs, in which functional IKK was
stably expressed in IKK/ cells, result in restored levels of
phosphorylated Ser10 levels with similar kinetics as wild-
type MEFs (Fig. 4E). Global levels of EGF-induced histone
H3 acetylation at Lys9 and Lys14 were slightly reduced in
IKK/ cells as compared with wild-type cells (Fig. 4E).
These data support a role for IKK in modulating global
levels of histone H3 phosphorylation on Ser10 in response to
mitogenic (EGF) stimuli.
p65/RelA Is Constitutively Associated with the c-fos Promoter
and Contributes to the Induction of c-fos Gene Expression—
Transcriptional regulation of c-fos is controlled by cis-acting
elements in the promoter regions, including the SRE and the
12-O-tetradecanoylphorbol-13-acetate response element (see
Ref. 23 and references therein). Full activation of the c-fos SRE
requires association with the ubiquitous transcription factor
SRF and formation of a complex with ternary complex factors,
including the Ets family of transcription factor Elk-1 (10).
Additionally, transactivation by these nuclear factors is facili-
tated by CBP/p300 (14). In terms of NF-B-dependent pro-
moter assembly, previous reports have demonstrated that
IKK interacts with CBP; however, recruitment of CBP to
NF-B-dependent promoters is not dependent on IKK (21). In
addition, utilizing p65/ MEFs, the p65 subunit was shown to
be required for IKK association with NF-B-regulated pro-
moters following TNF stimulation (20, 21). To explore the mode
of recruitment for IKK to the c-fos promoter, ChIP assays
were performed using antibodies against p65 and CBP. In
wild-type MEFs, p65 was detected at the c-fos promoter in
unstimulated cells, and this remained relatively unchanged
following EGF stimulation (Fig. 5A, left panel). A similar pro-
file of p65 association with the c-fos promoter was observed in
IKK/ MEFs (Fig. 5A, right panel). Consistent with previous
reports (see Ref. 14 and references therein); CBP is found
constitutively associated with the c-fos promoter in wild-type
MEFs (Fig. 5A, left panel). Additionally, CBP recruitment was
unaltered in cells deficient for IKK (Fig. 5A, right panel). p65
was not found associated with the -globin promoter (data not
shown), indicating the specificity of the ChIP assays. These
data indicate that p65 is preassociated with the c-fos promoter
in an IKK-independent manner.
To explore a potential role for p65 at the c-fos gene promoter,
quantitative real time PCR analysis was used to measure c-fos
FIG. 3. EGF-induced MAPK activa-
tion is unaffected in IKK/ MEFs.
Analysis of MAPK activation in EGF-
stimulated IKK wild-type and IKK/
MEFs. The cells were serum-starved for
48 h and treated with EGF (50 ng/ml) at
indicated time points. Western analysis
was performed with anti-phospho-
MEK1/2 (A, top panel) and antibodies
against MEK1 and tubulin (A, bottom
panel) as a loading control. B, kinetics of
EGF- induced Elk-1 phosphorylation lev-
els in IKK wild-type and IKK/ MEFs
were analyzed by Western with antibod-
ies against phospho-Elk-1(top panel) and
total Elk-1 (bottom panel).
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gene expression in p65/ MEFs following EGF treatment.
p65/ MEFs exhibited a marked defect in c-fos gene induction
after EGF treatment in contrast to wild-type MEFs that show
rapid induction of c-fos mRNA within 15 min of EGF stimula-
tion (Fig. 5B). These results indicate that p65 may play a direct
regulatory role in controlling c-fos gene expression or may
facilitate promoter-associated IKK or other factors to stimu-
late gene expression.
Association of IKK at the c-fos Promoter Occurs Independ-
ently of the p65 NF-B Subunit—The data described above
raise the question of whether p65 is required for the association
of IKK with the c-fos promoter. To address this point, ChIP
assays were performed in p65/ MEFs. Quiescent p65/
MEFs were left untreated or were treated with EGF along a
time course followed by ChIP analysis with antibodies against
IKK or phospho-Ser10 histone H3. Our data demonstrate in-
ducible levels of H3 Ser10 phosphorylation in response to EGF,
with peak levels after 15 min of EGF treatment (Fig. 5C).
Interestingly, peak levels of promoter-associated IKK were
detected after 10 min of EGF treatment, indicating that re-
cruitment of IKK at the c-fos promoter is p65-independent
(Fig. 5C). The results were confirmed by quantification of ChIP
DNA by real time PCR to measure the amount of c-fos genomic
DNA that co-immunoprecipitated with the H3 Ser10 phospho-
rylation levels in p65/ MEFs as well as wild-type MEFs
relative to total input chromatin (data not shown). Collectively,
FIG. 4. EGF-induced H3 Ser10 phos-
phorylation at the c-fos promoter re-
quires IKK recruitment. A, chroma-
tin was prepared from quiescent IKK
wild-type (left panel), IKK/ (middle
panel), or IKK/, IKK reconstituted
MEFs (right panel) that were treated
with EGF (50 ng/ml) at the indicated time
points. ChIP assays were performed using
anti-IKK, anti-phospho-Ser10 (H3-
pS10), anti-acetyl-Lys9 (H3-AcK9), or an-
ti-acetyl-Lys14 (H3-AcK14) as indicated.
c-fos promoter DNA sequences were de-
tected by semi-quantitative PCR. B–D,
chromatin was prepared from quiescent
IKK wild-type (black bars) or IKK/
(gray bars) MEFs that were treated with
EGF (50 ng/ml) at the indicated time
points. ChIP assays were performed using
anti-phospho-Ser10 (B), anti-acetyl-Lys14
(C), or anti-acetyl-Lys9 (D) as indicated.
c-fos promoter DNA sequences were de-
tected by quantitative real time PCR. The
data are presented as percentages of total
input. E, acid-soluble proteins were ex-
tracted from quiescent IKK wild-type
(WT), IKK/, and IKK/ MEFs and
immunoblotted with anti-phospho-Ser10,
anti-acetyl-Lys9, or anti-acetyl-Lys14 H3
antibodies. Coomassie staining of acid-
extracted histones was used to visualize
equal loading.
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these results indicate that EGF-induced recruitment of IKK
to the c-fos promoter occurs independently of p65/RelA.
DISCUSSION
The results presented in this report indicate that IKK is a
critical regulator of mitogenic-induced H3 Ser10 phosphoryla-
tion, at least for the c-fos promoter. The data also support
previously published work regarding the association between
inducible phosphorylation and acetylation at certain promoters
(17), whereby the loss of H3 Ser10 phosphorylation reduces but
does not eliminate inducible levels of acetylation of histone H3
in IKK/ MEFs. However, we do not exclude the possibility
that these dynamic modifications occur independently as pre-
viously reported for the c-jun promoter (24). In addition to
these dynamic modifications, interplay among other modifica-
tions, such as histone H3 methylation, may differentially con-
tribute to c-fos gene regulation either positively or negatively
(25, 26). The experiments also provide an interesting regula-
tory model whereby NF-B controls gene expression in a man-
ner that is independent of inducible promoter association of the
NF-B subunit, p65/RelA.
Evidence that IKK controls c-fos histone H3 phosphoryla-
tion and inducible gene expression led us to address the poten-
tial association of the p65 NF-B subunit with the c-fos pro-
moter, because it was previously found that IKK association
with certain cytokine-regulated promoters was dependent on
the recruitment of p65 (20, 21). Our current studies indicate
that p65 is found constitutively associated with c-fos promoter.
In this regard, the association of p65 with the c-fos promoter
occurs in a manner that is similar to other c-fos regulatory
factors (such as SRF) and that is different from the traditional
mechanism of NF-B regulation. Although others have ob-
served the classical NF-B activation response in cells that
express high levels of EGF receptor (8), at least in quiescent
MEFs, we did not observe any significant degradation of IB
or nuclear accumulation of p65 following treatment with EGF.
Interestingly, p65 contributed to the induced levels of c-fos
gene expression following EGF treatment of quiescent MEFs
(Fig. 5B). Thus, the role of the p65 subunit in controlling
EGF-induced gene expression is not dependent on the en-
hanced recruitment of this transcription factor with its gene
target. However, the mode of p65 activation downstream of
EGF and the role that p65 plays in regulating c-fos gene ex-
pression are presently unclear.
The basis for the association of p65 with the c-fos promoter is
unknown. Previous studies have suggested that p65 might
participate in regulating the transcriptional activity of SRF,
and a physical interaction was reported between p65 and SRF
in vitro (27). Thus, it is possible that p65 is constitutively
associated with the c-fos promoter through interactions with
SRF. Additionally, we identified a previously uncharacterized
NF-B consensus site in the c-fos promoter (positions 214 to
223). The position of the region amplified with c-fos promoter-
specific primer pairs used in the PCR step of the ChIP assays
includes this putative NF-B site. Electrophoretic mobility
shift assays did not detect NF-B DNA binding to this site in
the c-fos promoter (data not shown), suggesting that this site is
not a high affinity site for p65 in vitro and supports the possi-
bility that p65 may function in concert with other nuclear
factors at this promoter in vivo. Possibilities for promoter-
associated p65 include cooperative interactions with SRF re-
sulting in the formation of higher transcriptional complexes, as
described above. In fact, antibodies to p65 (but not to p50) can
partially supershift an SRF/SRE complex using a gel mobility
shift assay (data not shown).
Although the importance of chromatin modification, includ-
ing histone phosphorylation, in regulating gene expression is
well recognized (28–30), the regulation of and identity of fac-
tors that control these modifications often remain unclear.
Recent evidence, using MSK1/2 double knock-out MEFs, indi-
cate that MSK proteins control global levels of H3 Ser10 phos-
phorylation as well as inducible H3 Ser10 phosphorylation at
the c-jun promoter in response to mitogenic or stress stimuli
(19). Furthermore, our studies and those of Soloaga et al. (19)
indicate that the loss of inducible H3 Ser10 phosphorylation
results in deficient c-fos gene expression levels. It is intriguing
to speculate that this reduction may reflect the contribution of
H3 Ser10 phosphorylation to immediate early gene expression.
However, MSK1/2 and IKK may play other roles in controlling
c-fos gene expression. For example, MSK1 may play a role in
activating the function of p65 at the c-fos promoter, because it
has been proposed that MSK1 controls the phosphorylation of
p65 on Ser276 (31), an event important in the interaction of p65
with co-activators, such as CBP (32). This concept could reflect
a role for p65 and for MSK at the c-fos promoter in controlling
expression of immediate-early genes. Longer term experimen-
tation is directed toward understanding the complex regulatory
network involving MSK1/2 and IKK in controlling chromatin
FIG. 5. Promoter-associated p65/RelA contributes to the induc-
tion of c-fos gene expression. A, chromatin was prepared from qui-
escent IKK wild-type (left panel) or IKK/ (right panel) MEFs that
were treated with EGF (50 ng/ml) at the indicated time points. ChIP
assays were performed using anti-p65 or anti-CBP as indicated. c-fos
promoter DNA sequences were detected by semi-quantitative PCR. B,
real time PCR analysis was performed to measure the endogenous
levels of c-fos mRNA in EGF stimulated wild-type or p65/ MEFs.
Quiescent cells were treated with EGF at the indicated time points,
similar to A. The values are reported as molecules of c-fos per attomol
of 18 S rRNA copies. C, EGF-induced recruitment of IKK at the c-fos
promoter occurs independently of p65. Chromatin was prepared from
quiescent p65/ MEFs that were treated with EGF (50 ng/ml) at the
indicated time points. ChIP assays were performed using anti- IKK or
anti-phospho-Ser10 as indicated. c-fos promoter DNA sequences were
detected by semi-quantitative PCR.
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modification and ultimately inducible gene expression.
The loss of p65 did not affect promoter-associated IKK or
EGF-induced H3 Ser10 phosphorylation at the c-fos promoter
(Fig. 5C). This result was surprising as compared with our
previous findings and those by Yamamoto et al. (21) where
recruitment of IKK to cytokine-inducible promoters is re-
quired the presence of p65. Thus, the mechanism of IKK
recruitment to the c-fos promoter could be dependent on the
presence of another NF-B subunit or via interactions with a
distinct factor. It is important to note that IKK interacts with
the transcriptional co-activator CBP (21) and that this inter-
action may underlie promoter recruitment. In this regard,
MAPK-directed phosphorylation of Elk-1 that stabilizes CBP/
p300 interactions with the SRE ternary complex (14) may also
lead to enhanced association of IKK with the c-fos promoter.
Collectively, our findings provide the first evidence that pro-
moter association of IKK can occur in a p65-independent
manner and that both IKK and p65 contribute to EGF-in-
duced c-fos gene expression. In this regard, IKK has been
shown to control keratinocyte differentiation in a manner that
is independent of NF-B (33). Additionally, IKK knock-out
mice exhibited skin and skeletal abnormalities (34), consistent
with the effect on keratinocyte differentiation. Overall, our
results indicate that both IKK and p65 contribute toward
maximal EGF-induced c-fos gene expression, potentially
through distinct mechanisms. This is consistent with previous
reports highlighting the complexity of c-fos gene regulation
through multiple promoter-bound factors and/or specific sig-
naling pathways (10).
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